AR
TEVA icon

Advisory Research’s Teva Pharmaceuticals TEVA Stock Holding History

Advisory Research’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,089
Closed -$185K – 470
2023
Q3 		$185K Buy
+18,089
New +$168K 0.03% 420
2017
Q3 		– Sell
-24,550
Closed -$816K – 472
2017
Q2 		$816K Buy
+24,550
New +$760K 0.01% 333

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Advisory Research's TEVA Position: Q4 2023 in Review

Advisory Research sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 18,089 shares — an estimated $185K sold.

Advisory Research first reported a position in TEVA in Q2 2017 and held it in 2 quarters. The position peaked at $816K in Q2 2017. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Advisory Research reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Advisory Research sold 18,089 Teva Pharmaceuticals shares in Q4 2023, an estimated $185K.
  • Advisory Research first reported a position in Teva Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Advisory Research's Teva Pharmaceuticals position peaked at $816K in Q2 2017.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Advisory Research's 13F filing for Q4 2023, filed 13 Feb 2024.